GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the likes of Moderna and BioNTech.

Genesis Therapeutics’ shiny AI drug discovery platform GEMS is catching on, having now caught the eye of Gilead Sciences.

Johnson & Johnson is collating its pantheon of medtech brands under a single banner, to further simplify the company’s presentation.

With a strong track record for identifying diamonds in the rough, Bain Capital Life Sciences (BCLS) has become a powerful force in biotech investing, pulling in more funding for each of its big-money rounds.

Relay Therapeutics has beaten its survival goal in a first-in-human breast cancer study, positioning the biotech to move into a pivotal trial that could establish its candidate as a challenger to AstraZeneca’s Truqap.

AstraZeneca has used artificial intelligence to devise a unique biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), hoping to differentiate the antibody-drug conjugate (ADC) from competitors while offering an explanation why the TROP2-directed therapy appears to work only in some non-small cell lung cancer (NSCLC) patients.

After overseeing the $4.1 billion sale of radiopharma player RayzeBio to Bristol Myers Squibb, biotech veteran Ken Song, M.D., didn’t take long to set up his next big venture. He is now chairman, president and CEO of Candid Therapeutics, which has debuted with a $370 million series A and a goal to dominate the T-cell engager market.

Just over a year after launching with $33 million in seed funding, Boston-based Superluminal Medicines is supercharging its small-molecule drug development with a $120 million series A round backed by the likes of Eli Lilly.

Psyence Biomedical is paying $500,000 in shares to acquire fellow psilocybin-based biotech Clairvoyant Therapeutics and its phase 2-stage alcohol use disorder (AUD) candidate.

After revealing plans to hit the U.S. public markets less than a month ago, Zenas Biopharma and Bicara Therapeutics have mapped out the details behind their planned initial public offerings.